Macquarie Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Macquarie Group’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-203	Closed	-$3K	–	1935
2019 Q2	$3K	Buy	+203	New	+$3.07K	﹤0.01%	1820
2019 Q1	–	Sell	-633	Closed	-$9K	–	2095
2018 Q4	$9K	Buy	633 +444	+235%	+$7.82K	﹤0.01%	1948
2018 Q3	$4K	Buy	+189	New	+$5.75K	﹤0.01%	2095

Other funds holding LUMO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

RCM

Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group's LUMO Position: Q3 2019 in Review

Macquarie Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2019, closing a stake of 203 shares — an estimated $3K sold.

Macquarie Group first reported a position in LUMO in Q3 2018 and held it in 3 quarters. The position peaked at $9K in Q4 2018. 68 funds tracked by Wall St. Rank hold LUMO as of Q3 2019.

Macquarie Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Macquarie Group sold 203 Lumos Pharma, Inc. Common Stock shares in Q3 2019, an estimated $3K.
Macquarie Group first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
Macquarie Group's Lumos Pharma, Inc. Common Stock position peaked at $9K in Q4 2018.
68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2019.

Based on Macquarie Group's 13F filing for Q3 2019, filed 14 Nov 2019.